MarketCapTrends
TXG
10x Genomics Inc. (TXG)
NASDAQ · Healthcare

10x Genomics Inc. Shareholder Equity 2017–2025

10x Genomics Inc. annual/quarterly shareholder equity history from 2018 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • 10x Genomics Inc. shareholder equity for the quarter ending December 31, 2025 were 796.3M, a 12.14% increase year-over-year.
  • 10x Genomics Inc. shareholder equity for 2025 were 796.3M, a 12.14% increase from 2024.
  • 10x Genomics Inc. shareholder equity for 2024 were 710.1M, a 4.17% decrease from 2023.
  • 10x Genomics Inc. shareholder equity for 2023 were 741.0M, a 8.03% decrease from 2022.
  • 10x Genomics Inc. shareholder equity for 2022 were 805.7M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
10x Genomics Inc. Annual Shareholder Equity (Millions of US $)
2025$796
2024$710
2023$741
2022$806
2021$818
2020$739
2019$420
2018$-220
10x Genomics Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$796
2024-12-31$710
2023-12-31$741
2022-12-31$806
2021-12-31$818
2020-12-31$739
2019-12-31$420
2018-12-31$-220

10x Genomics Inc. Shareholder Equity — FAQ

10x Genomics Inc. (TXG) shareholder equity over the last 9 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see TXG's shareholder equity history?

The chart and table above show 10x Genomics Inc.'s shareholder equity by year and by quarter, including the growth rate.